title: Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
authors.forename: S
authors.initials: S
authors.lastname: Pusceddu
authors.forename: R
authors.initials: R
authors.lastname: Buzzoni
authors.forename: F
authors.initials: F
authors.lastname: De Braud
mesh_terms: D006801:Humans; D007414:Intestinal Neoplasms / Q000175:diagnosis*; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis*; D018358:Neuroendocrine Tumors / Q000175:diagnosis*; D010190:Pancreatic Neoplasms / Q000175:diagnosis*; D013274:Stomach Neoplasms / Q000175:diagnosis*